Trelegy Ellipta

Pharma

After trial fail, Teravance is bought out by Zymeworks for $929M

Four months after Theravance Biopharma signaled it was up for sale, the Dublin-based company has agreed to be bought out by Zymeworks for $929 million.

Kevin Dunleavy Jun 29, 2026 11:30am

pay deal hand over cash licensing transaction money

Theravance sells remaining Trelegy royalties to GSK for $225M

Jun 2, 2025 9:18am

Hand holding blue asthma inhaler with spray coming out

AZ's Breztri set up for label expansion with 2 asthma trial wins

May 2, 2025 11:30am

Man holding remote control in dark room with TV and red and blue lights

AbbVie's Rinvoq tops TV drug ad spenders' list

Jun 6, 2023 9:15am

AbbVie continues top TV drug ad spender reign

Oct 10, 2022 10:57am

GSK, E&I report finds dissatisfaction with asthma management

Sep 9, 2022 7:30am